CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
Ovarian cancer is the most-deadly gynecologic malignancy, with greater than 14,000 women expected to succumb to the disease this year in the United States alone. In the front-line setting, patients are treated with a platinum and taxane doublet. Although 40–60% of patients achieve complete clinical...
Main Authors: | Justin W. Gorski, Frederick R. Ueland, Jill M. Kolesar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/10/5/279 |
Similar Items
-
CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis
by: Xingyu Zheng, et al.
Published: (2023-03-01) -
SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway
by: Pan Xu, et al.
Published: (2022-01-01) -
Regulatory Effect of miR497-5p–CCNE1 Axis in Triple-Negative Breast Cancer Cells and Its Predictive Value for Early Diagnosis [Retraction]
by: Liu WW, et al.
Published: (2023-11-01) -
RETRACTED: Knockdown of Long Non-Coding RNA KCNQ1OT1 Restrained Glioma Cells’ Malignancy by Activating miR-370/CCNE2 Axis
by: Wei Gong, et al.
Published: (2017-03-01) -
<i>CCNE1</i> Is a Putative Therapeutic Target for <i>ARID1A</i>-Mutated Ovarian Clear Cell Carcinoma
by: Naoki Kawahara, et al.
Published: (2021-05-01)